GleamWall
中文EN

LENZ LENZ Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815776 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-29.4%
TTM net income YoY-138.2%
TTM EPS YoY-119.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin82.0%
Operating margin-1,211.2%
Net margin-1,135.0%
FCF margin-1,033.3%
EBITDA margin-1,207.6%

Returns

ROE-72.7%
ROA-66.7%
ROIC (approx.)-71.7%
Asset turnover0.06x

Leverage & solvency

Liabilities / assets8.5%
Debt / equity0.00x
Current ratio11.66x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue0.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$3.38M$5.49M$1.90M$1.59M$12.50M$5.00M$0$0
Cost of revenue$454,000$280,000$1.08M$418,000$0$0$0—
Gross profit$2.93M$5.21M$825,000$1.17M$12.50M$5.00M$0—
R&D expense$0$0$0$0$3.79M$9.06M$5.82M$5.87M
SG&A expense$35.85M$39.38M$44.96M$39.63M$27.60M$12.80M$11.11M$9.36M
Operating income-$32.92M-$34.17M-$44.13M-$38.46M-$18.89M-$16.86M-$16.93M-$15.22M
Pretax income-$30.97M-$31.91M—-$35.89M-$16.70M-$14.41M—-$12.65M
Income tax$0$3,000—$2,000$0$500,000—$1,000
Net income-$30.97M-$31.92M-$41.49M-$35.90M-$16.70M-$14.91M-$14.62M-$12.65M
EBITDA-$32.81M-$34.06M-$44.02M-$38.36M-$18.76M-$16.84M-$16.89M-$15.20M
EPS (basic)-0.99-1.02-1.32—-0.59-0.53-0.53—
EPS (diluted)-0.99-1.02-1.32—-0.59-0.53-0.53—
Weighted avg. shares (diluted)31.42M31.37M31.35M—28.54M28.08M27.53M—
Balance sheet
Cash & equivalents$30.55M$24.21M$24.77M$25.18M$25.40M$37.61M$23.04M$20.16M
Receivables$913,000$442,000$343,000$329,000———$0
Inventory$4.76M$4.12M$3.50M$2.94M$949,000——$0
Current assets$206.90M$233.28M$268.37M$301.41M$207.00M$213.60M$197.86M$211.92M
PP&E, net$640,000$1.00M$1.10M$1.19M$1.26M$1.17M$926,000$651,000
Total assets$209.75M$236.60M$272.54M$305.88M$210.70M$217.33M$201.25M$215.30M
Current liabilities$17.75M$17.21M$25.81M$21.19M$16.32M$10.40M$8.57M$10.41M
Total liabilities$17.75M$17.33M$26.04M$21.54M$16.78M$10.97M$9.24M$11.22M
Shareholders' equity$192.00M$219.26M$246.49M$284.34M$193.93M$206.37M$192.01M$204.08M
Shares outstanding31.42M31.42M31.35M31.34M28.59M28.50M27.54M27.52M
Cash flow statement
Operating cash flow-$22.31M-$38.71M-$33.58M-$33.02M-$8.59M-$11.51M-$16.05M-$9.08M
Capital expenditure$0$16,000$18,000$38,000$439,000$240,000$110,000$149,000
Free cash flow-$22.31M-$38.73M-$33.60M-$33.06M-$9.03M-$11.75M-$16.16M-$9.23M
Investing cash flow$28.66M$37.75M$33.16M-$89.81M-$4.33M-$414,000$18.89M-$11.86M
Financing cash flow$0$395,000$14,000$122.61M$598,000$26.49M$44,000$53,000
Depreciation & amortization$109,000$110,000$111,000$107,000$125,000$19,000$36,000$25,000
Stock-based compensation$4.13M$4.47M$4.32M$3.68M$3.47M$2.85M$2.56M$1.63M

Free plan shows the latest 8 periods; Pro shows all 26 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.